Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China.

Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL.

World J Hepatol. 2019 May 27;11(5):421-441. doi: 10.4254/wjh.v11.i5.421. Review.

2.

The impact of hepatitis C virus outside the liver: Evidence from Asia.

Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, Mondelli MU.

Liver Int. 2017 Feb;37(2):159-172. doi: 10.1111/liv.13272. Epub 2016 Nov 10. Review.

PMID:
27748564
3.

Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence.

Nuño Solinís R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y.

Infect Dis Ther. 2016 Dec;5(4):491-508. Epub 2016 Oct 25. Review.

4.

Direct-Acting Antiviral Agents for Chronic Hepatitis C Genotype 1 [Internet].

Murphy G, Farah B, Wong W, Krahn M, Wells G, Chen L, Kelly S, Kaunelis D, Blouin J, Lee K, Carrie A.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Oct.

5.

Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.

Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS.

Cochrane Database Syst Rev. 2017 Mar 13;3:CD011644. doi: 10.1002/14651858.CD011644.pub2. Review. Update in: Cochrane Database Syst Rev. 2018 Dec 03;12:CD011644.

6.

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 Jun 17;(6):CD011132. doi: 10.1002/14651858.CD011132.pub2. Review.

PMID:
24937404
7.

Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.

Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, Zhao J, You SL, Hu JH, Liu JL, Niu XX, Chen J, Lu L, Wu V, Lau G.

Hepatol Int. 2016 Sep;10(5):789-98. doi: 10.1007/s12072-016-9755-0. Epub 2016 Jul 21.

PMID:
27443347
8.

All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.

Shahid I, Ibrahim MM.

Curr Mol Med. 2018;18(7):409-435. doi: 10.2174/1566524019666190104110439.

PMID:
30608042
9.

The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.

Bickerstaff C.

Expert Rev Pharmacoecon Outcomes Res. 2015 Aug 9:1-14. [Epub ahead of print]

PMID:
26256412
10.

Direct-acting antivirals for chronic hepatitis C.

Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C.

Cochrane Database Syst Rev. 2017 Jun 6;6:CD012143. doi: 10.1002/14651858.CD012143.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Sep 18;9:CD012143.

11.

Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?

Premkumar M, Grover GS, Dhiman RK.

J Clin Exp Hepatol. 2017 Sep;7(3):253-261. doi: 10.1016/j.jceh.2017.08.003. Epub 2017 Sep 23. Review.

12.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
13.

The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?

Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC.

Liver Int. 2017 May;37(5):662-668. doi: 10.1111/liv.13298. Epub 2016 Nov 29.

PMID:
27804195
14.

Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.

Lo AO, Chan HL, Wong VW, Wong GL.

J Gastroenterol Hepatol. 2017 May;32(5):1071-1078. doi: 10.1111/jgh.13638.

PMID:
28449343
15.

[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].

Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Rókusz L, Szalay F, Telegdy L, Tornai I, Werling K, Makara M.

Orv Hetil. 2015 Mar 1;156(9):343-51. doi: 10.1556/OH.2015.30106. Review. Hungarian.

PMID:
25702254
16.

A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.

Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R.

J Hepatol. 2013 Nov;59(5):926-33. doi: 10.1016/j.jhep.2013.06.019. Epub 2013 Jun 26.

PMID:
23811030
17.

Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.

Nakamoto S, Kanda T, Shirasawa H, Yokosuka O.

World J Hepatol. 2015 May 18;7(8):1133-41. doi: 10.4254/wjh.v7.i8.1133. Review.

18.

Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.

Younossi Z, Henry L.

Aliment Pharmacol Ther. 2015 Mar;41(6):497-520. doi: 10.1111/apt.13090. Epub 2015 Jan 23. Review.

19.

The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.

Bickerstaff C.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):787-800. doi: 10.1586/14737167.2015.1076337. Epub 2015 Aug 9. Review.

PMID:
26289734
20.

Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort.

Liu TW, Tsai PC, Huang CI, Tsai YS, Wang SC, Ko YM, Lin CC, Chen KY, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML.

J Formos Med Assoc. 2018 Jan;117(1):54-62. doi: 10.1016/j.jfma.2017.02.013. Epub 2017 Apr 4.

Supplemental Content

Support Center